ETIDIOH - NEW

  September 2025   The development of influenza candidate vaccine viruses (CVVs), coordinated by WHO, remains an essential component of the overall global strategy for influenza pandemic preparedness . Selection and development of CVVs are the first steps towards timely vaccine production and do not imply a recommendation for initiating manufacture . National authorities may consider the use of one or more of these CVVs for pilot lot vaccine production , clinical trials and other pandemic preparedness purposes based on their assessment of public health risk and need.  Zoonotic influenza viruses continue to be identified and evolve both antigenically and genetically, leading to the need for additional CVVs for pandemic preparedness purposes.  Changes in the antigenic and genetic characteristics of these viruses relative to existing CVVs and their potential risks to public health justify the need to develop new CVVs. This document summarizes the antigenic and genetic c...

  Highlights     • This Situation report will now be published monthly.  • All clades of the monkeypox virus (MPXV) continue to circulate. When mpox outbreaks are not rapidly contained and human-to-human transmission is not interrupted, there is a risk of sustained community transmission.   • In September 2025, 42 countries , across all WHO regions, reported a total of 3135 confirmed cases , including 12 deaths (case fatality ratio [CFR] 0.4%). More than 80% of these cases were reported in the African Region . Four regions (African Region, Eastern Mediterranean Region, Region of the Americas, and the Western Pacific) observed a declining trend in confirmed cases reported per month, while the European and South-East Asian regions observed an increase in cases in September 2025. • Seventeen countries in Africa have experienced ongoing active transmission of mpox in the last six weeks (14 Sep – 19 Oct 2025), with 2862 confirmed cases, including 17 deaths (CFR ...

  {Excerpt} Risk statement This risk assessment is based on the current epidemiological and epizootic situation of Rift Valley fever (RVF) in Senegal and Mauritania , from 20 September through 8 October 2025. The risk assessment was conducted separately for each country . However, the findings indicate that the level of risk is the same for both countries across all levels, for both human and animal health .   During this period , Senegal reported 119 confirmed human RVF cases , including 16 deaths , resulting in a case fatality rate (CFR) of 13.4% . Cases were recorded across eight health districts in three regions of Senegal, with the majority in Saint-Louis Region with 110 cases (92%) followed by Louga (four cases) and Matam (one case).  The affected districts in Saint-Louis Region : Podor, Richard-Toll, Dagana, and Saint-Louis are located along the northern border with Mauritania along the Senegal River.   The most affected age groups were 15- 35 years ...

  PURPOSE AND SCOPE   -- With the initiation of the first phase of the ceasefire , humanitarian needs remain dire.  -- In the current situation , it is crucial to scale up humanitarian aid in a coordinated manner while ensuring the start of early recovery and reconstruction.  -- This document summarizes WHO’s key planning assumptions , strategic priorities and selected activities.  -- The activities fall within the scope of the overall 2025 WHO operational response and early recovery plan for the occupied Palestinian territory and the One-UN multi-sectoral Gaza Ceasefire Humanitarian Response Plan Summary 60 days (13 October 2025). ASSUMPTIONS   -- This plan is developed under the following assumptions :   - Continuation of ceasefire and improvement of the law-and-order situation. - Improved access for UN with access/registration issues for INGOs remaining. - Gradual emergence of a clear and functional governance structure.  - Improved flexi...

  Abstract The SARS outbreak and influenza A(H5N1) infections (2003–2004) prompted WHO to establish a global influenza antiviral stockpile , enabling rapid distribution to 72 countries during the 2009 A(H1N1) pandemic. To improve access in low- and middle-income countries, WHO added antivirals to the WHO Model List of Essential Medicines and included them in the Prequalification Programme . The 2011 Pandemic Influenza Preparedness Framework refined strategies for equitable access and rapid response. Lessons from COVID-19 led to a new WHO-led mechanism—the Interim Medical Countermeasures Network (i-MCM-net)— which supports integrated supply chains, real-time data sharing, research and development, and equitable access. WHO continues to emphasise equity and global solidarity , highlighting the need for accessible, effective, and affordable antivirals alongside vaccines to protect vulnerable populations and mitigate the impact of future pandemics. Source: Journal of Infectious Disease...

  New human cases {1,2}:  -- From 26 August to 29 September 2025 , based on reporting date, the detection of influenza A(H5) in one human , influenza A(H5N1) in one human , influenza A(H9N2) in eight humans and an influenza A(H1N1) variant ((H1N1)v) virus in one human were reported officially.   Circulation of influenza viruses with zoonotic potential in animals :  -- High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3}  -- The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4}  Risk assessment {5}:  -- Sustained human to human transmission has not been reported from these events.  -- Based on information available at the time of this risk assessment update , the overall public health risk from currently known influenza A viruses d...

  Situation at a glance In 2025, a resurgence of chikungunya virus (CHIKV) disease was noted in a number of countries , including some that had not reported substantial case numbers in recent years.  Between 1 January and 30 September 2025, a total of 445 271 suspected and confirmed CHIKV disease cases and 155 deaths were reported globally from 40 countries , including autochthonous and travel imported cases.  Some WHO Regions are experiencing significant increases in case numbers compared to 2024, although others are currently reporting lower case numbers.  This uneven distribution of cases across regions makes it challenging to characterize the situation as a global rise, however, given the ongoing outbreaks reported globally in 2025, the potential for further spread remains significant .  CHIKV disease can be introduced into new areas by infected travelers and local transmission may be established if there is the presence of Aedes mosquito and a susceptible p...